Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.

This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

This research used computational methods to identify potential new treatments for benign prostatic hyperplasia, finding three compounds from Ghanaian plants with promising binding energy against 5alpha reductase 2 compared to existing drugs, yet further in vitro validation is necessary to confirm their efficacy.

This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.

This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.

This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

This study identified several herbs, including Ganoderma lucidum and Urtica dioica, that showed promising 5α-reductase inhibitory activity suggesting potential use in managing androgenic disorders.

This study found that exercise decreases the expression of 5αR1, thereby enhancing the PI3K/AKT signaling pathway in PCOS rats.

This study found that finasteride treatment reduced caspase-1 expression, suggesting that androgens may influence immune processes in the hair cycle of androgenetic alopecia.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

This study observed that female mice with disrupted 5α-reductase 1 showed increased insulin resistance and hepatic steatosis, suggesting altered glucocorticoid metabolism contributes to metabolic disorders.

This study identified proteins that are differentially expressed in balding versus non-balding dermal papilla cells, potentially aiding the understanding and treatment of androgenetic alopecia.

This review discusses various chromatographic methods for analyzing finasteride in biological fluids and provides no clinical findings, focusing on detection techniques for different concentration levels.

In this study, microneedling with a depth of 0.6 mm, alongside minoxidil, significantly improved hair count and thickness in patients with androgenetic alopecia compared to minoxidil alone, and was more beneficial than a 1.2 mm depth.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study reports that a 30% ethanol extract of a plant mixture enhanced hair growth in human hair dermal papilla cells and mice, suggesting potential use in hair growth products.

In this study, finasteride was found not to be associated with changes in sleep spindle activity or morphology in men undergoing sleep studies.